

MATERIAL CHANGE NOTICE SUBMISSION DETAILS

MCN Number	2026-01-07-1465
OHCA Review Start Date	January 15, 2026
Anticipated date (unless tolled per regulation) by which OHCA could waive cost and market impact review	March 23, 2026
Anticipated date (unless tolled per regulation) by which OHCA could determine cost and market impact review required	April 6, 2026

SUBMITTER

HEALTH CARE ENTITY CONTACT FOR PUBLIC INQUIRY

Title	Associate
First Name	Deepika
Last Name	Raj
Email Address	draj@mwe.com
Street Address	2049 Century Park East
City	Los Angeles
State	CA
Postal Code	90067

GENERAL

Business Name	Abbott Laboratories
Website	https://www.abbott.com/en-us/homepage
Ownership Type	Corporation
Tax Status	For-profit
Federal Tax ID	36-0698440
Description of Submitting Organization	<p>Abbott Laboratories (NYSE: ABT) (“Abbott” or “Parent”) is an international company that manufactures and sells diagnostics, medical devices, nutritional products and branded generic pharmaceuticals. As further described in this filing, Abbott and Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences” or the “Seller”) entered into an Agreement and Plan of Merger (“Agreement”) for Abbott to acquire Exact Sciences through the merger of Abbott’s subsidiary, Badger Merger Sub I, Inc., with and into Exact Sciences, with Exact Sciences surviving the Merger as a wholly owned subsidiary of Abbott (the “Proposed Transaction”).</p> <p>As further described in the supplemental summary attached to this filing, Abbott, through the subsidiaries described below, has the following separate lines of business in California that serve patients in all California counties: (i) one dedicated toxicology clinical laboratory separately incorporated as Redwood Toxicology Laboratory, Inc., (ii) one Independent Diagnostic Testing Facility (“IDTF”) separately incorporated as Alere Home Monitoring, Inc., that conducts business as Acelis Connected Health Services, and (iii) one specialized durable medical</p>

	equipment (“DME”) business separately incorporated as Quality Assured Services, Inc., that conducts business as Acelis Connection Health Supplies (collectively, the “Existing California Service Lines”). While this notice contains information about the health care services that Abbott provides in California through its subsidiaries, the material change transaction described below will not affect Abbott’s Existing California Service Lines, as further described in other portions of this filing.
Health Care Provider	Yes
For Providers: Desc. of Capacity or Patients served in California	Please see supplemental response.

LOCATIONS

Counties	All Counties
California licenses and numbers	Please see supplemental response.
Other States Served	AK; AL; AR; AZ; CO; CT; DC; DE; FL; GA; HI; IA; ID; IL; IN; KS; KY; LA; MA; MD; ME; MI; MN; MO; MS; MT; NC; ND; NE; NH; NJ; NM; NV; NY; OH; OK; OR; PA; RI; SC; SD; TN; TX; UT; VA; VT; WA; WI; WV; WY
Other state(s) licenses and numbers	Please see supplemental response.
Primary Languages used when providing services	English; Spanish

MATERIAL CHANGE

ADDITIONAL ENTITIES

Business Name	Description of the Organization	Ownership Type	Additional MCN Submission
Exact Sciences Corporation	Exact provides cancer screening and diagnostics services to patients in the entire state of California. It owns a clinical lab in Redwood City, CA, and has 918 FTEs in California. Exact does not track the number of patients served but does track, and is providing in a separate Excel file, test volume data, filed as a part of Exact's MCN filing.	Corporation	Yes
Badger Merger Sub I, Inc.	N/A - Badger Merger Sub I, Inc. is a newly formed entity created for the purpose of effectuating the merger described herein. It does not have any operations or revenue and it has not been involved in any other transactions.	Corporation	No

CRITERIA

A health care entity with annual revenue, as defined in section 97435(d) , of at least \$25 million or that owns or controls California assets of at least \$25 million, or;	Yes
A health care entity with annual revenue, as defined in section 97435(d) , of at least \$10 million or that owns or controls California assets of at least \$10 million and is a party to a transaction with any health care entity satisfying subsection (b)(1), or	Yes

CIRCUMSTANCES FOR FILING

The proposed fair market value of the transaction is \$25 million or more and the transaction concerns the provision of health care services.	Yes
The transaction is more likely than not to increase annual California-derived revenue of any health care entity that is a party to the transaction by either \$10 million or more or 20% or more of annual California-derived revenue at normal or stabilized levels of utilization or operation.	Yes
The transaction involves the sale, transfer, lease, exchange, option, encumbrance, or other disposition of 25% or more of the total California assets of the submitter(s).	Yes

TRANSACTION DETAILS

Anticipated Date of Transaction Closure	4/7/2026
Description of the Transaction	Please see attached supplemental response.
Submitted to US Department of Justice or Federal Trade Commission?	Yes
Date of Submission	1/6/2026
Description of the Submission	A Hart-Scott-Rodino Filing (HSR) was made with the FTC and DOJ on January 6, 2026.
Submitted to Other Agency?	Yes
Date of Submission	1/7/2026
To Whom Submitted	See "Description of Submission" section.
Description of Submission (Include Agency name(s) and State(s))	The parties also will make the following U.S. state filings, either jointly or separately, as applicable: a Notice of Material Change Transaction with the Oregon Health Authority; a Notice of Material Change with the Massachusetts Health Policy Commission; a Notice of Transaction with the Indiana Office of the Attorney General; and a Material Transaction Notice with the New York Department of Health.
Subject to court proceeding	No
Description of current services provided and expected post-transaction impacts on health care services	Please see supplemental filing.
Prior mergers or acquisitions that: (A) involved the same or related health care services; (B) involved at least one of the entities, or their parents, subsidiaries, predecessors, or successors, in the proposed transaction; and (C) were closed in the last ten years.	Pursuant to an Agreement and Plan of Merger dated January 30, 2016, as amended February 2, 2016, and April 13, 2017, Abbott Laboratories, an Illinois corporation ("Abbott"), Angel Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott ("Merger Sub"), and Alere, Inc., a Delaware corporation ("Alere"), on October 3, 2017, Merger Sub merged into Alere with Alere as the surviving corporation as a subsidiary of Abbott, for total consideration of \$5.3 billion.
Description of Potential Post Transaction Changes	Please see supplemental filing.
Description of the nature, scope, and dates of any pending or planned material changes occurring between the Submitter and any other entity, within the 12 months following the date of the notice	The submitter does not have any currently pending material change transactions. The parties do not anticipate any material change transactions between the submitted and any other entity that are planned to occur within 12 months following the date of the notice.

Description of Submitting Organization

Abbott Laboratories (NYSE: ABT) (“Abbott” or “Parent”) is an international company that manufactures and sells diagnostics, medical devices, nutritional products and branded generic pharmaceuticals. As further described in this filing, Abbott and Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences” or the “Seller”) entered into an Agreement and Plan of Merger (“Agreement”) for Abbott to acquire Exact Sciences through the merger of Abbott’s subsidiary, Badger Merger Sub I, Inc., with and into Exact Sciences, with Exact Sciences surviving the Merger as a wholly owned subsidiary of Abbott (the “Proposed Transaction”).

As further described in the supplemental summary attached to this filing, Abbott, through the subsidiaries described below, has the following separate lines of business in California that serve patients in all California counties: (i) one dedicated toxicology clinical laboratory separately incorporated as Redwood Toxicology Laboratory, Inc., (ii) one Independent Diagnostic Testing Facility (“IDTF”) separately incorporated as Alere Home Monitoring, Inc., that conducts business as Acelis Connected Health Services, and (iii) one specialized durable medical equipment (“DME”) business separately incorporated as Quality Assured Services, Inc., that conducts business as Acelis Connection Health Supplies (collectively, the “Existing California Service Lines”). While this notice contains information about the health care services that Abbott provides in California through its subsidiaries, the material change transaction described below will not affect Abbott’s Existing California Service Lines, as further described in other portions of this filing.

Toxicology Lab Business

Abbott owns and operates four dedicated toxicology clinical laboratories in the U.S.: Redwood Toxicology in Santa Rosa, CA (NPI# 1891792875), Alere Toxicology in Gretna, LA, Alere Toxicology in Richmond, VA (NPI# 1689874893), and Ascertain Forensics. Abbott’s toxicology laboratories provides services in all 50 states.

Abbott’s U.S. toxicology laboratory business has the following major segments: (1) U.S. Workplace Solutions, (2) U.S. Government and (3) U.S. Reagents.

(1) U.S. Workplace Solutions offers a drug and alcohol testing and pre-employment physical occupational health business for employers and third party administrators that includes a network of third-party clinics and collection sites, POCT kits, on-site specimen collection services, lab services, lab reagent drug-testing products, and proprietary digital platforms that connect the end-to-end process. The services provided are for employment verification and not for clinical or diagnostic purposes.

(2) U.S. Government segment provides lab services, rapid tests, and the proprietary ToxAccess® platform to enable U.S. federal, state, and local government agencies to efficiently and effectively manage drug testing programs.

(3) U.S. Reagents segment manufactures drugs of abuse assays for urine and oral fluid sample types for clinical labs, reference labs, treatment centers, forensic labs, and segments of the judicial system.

Acelis Connected Health

Abbott’s Acelis business includes (1) International Normalized Ratio (“INR”) testing services, (2) ventricle assisted device (“VAD”) equipment and supplies, and (3) related digital offerings.

(1) Through its INR business, Acelis provides remote patient monitoring PT-INR (prothrombin time - international normalized ratio) anticoagulation services for patients on anticoagulation medicines.

(2) Through the VAD business, Acelis provides external VAD equipment and supplies for outpatient support and remote patient monitoring if selected as a contract option.

(3) Both the INR and VAD businesses also include digital offerings. CoagClinic is a software as a service offering by Acelis that it licenses to healthcare providers. Healthcare providers use CoagClinic to manage Acelis INR patients and to access Acelis records and related data for those patients, including their reported self-test INR results. VADWatch is also a software as a service offering available to Acelis customers who wish to remotely monitor patients implanted with a VAD. VADWatch also allows for healthcare providers to track equipment inventory. HealthCheck is the mobile version of CoagClinic or VADWatch and provides patients (through HealthCheck) and healthcare providers (through HealthCheck Pro) with the option of using each offering's features through an app.

Governance and operational structure

Abbott is governed by a board of directors currently consisting of 11 independent directors and Abbott CEO Robert B. Ford who serves as the Chairman of the Board. Abbott's Executive Team consists of CEO Robert B. Ford and 19 Executive Vice Presidents or Senior Vice Presidents.

The following U.S. Abbott entities own health care entities. Please see **Attachment F** for organizational charts showing the organization's structure.

Toxicology Lab Business- *United States*

- eScreen, Inc.
- Global Analytical Development LLC
- Instant Technologies, Inc.
- Redwood Toxicology Laboratory, Inc.
- Alere Toxicology Services, Inc.

Acelis Connected Health

- Alere Home Monitoring, Inc. (d/b/a Acelis Connected Health Services)
- Quality Assured Services, Inc. (d/b/a Acelis Connected Health Supplies)

For health care providers or fully integrated delivery systems - Provide a summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic services area(s), and capacity or patients served in California (e.g., number of licensed beds, number of patients per county in the last year)

See Attachment L.

California health care-related license and registration types and numbers

See Attachment N.

Other states where health care-related licenses are held and license type

See Attachment N.

Goals of the Transaction

On November 19, 2025, Abbott Laboratories (NYSE: ABT) (“Abbott” or “Parent”) and Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences” or the “Seller”) entered into an Agreement and Plan of Merger (“Agreement”) for Abbott to acquire Exact Sciences through the merger of Abbott’s subsidiary, Badger Merger Sub I, Inc., with and into Exact Sciences, with Exact Sciences surviving the Merger as a wholly owned subsidiary of Abbott (the “Proposed Transaction”). The parties entered into the Agreement to accelerate innovation and expand access to diagnostics focused on cancer screening, with a goal to help more people detect and manage cancer during its earliest stages. The transaction will enable Abbott to enter the fast-growing advanced cancer diagnostics segment, serving millions more people.

Summary of terms of the transaction

As described above, the Proposed Transaction will be effected via Badger Merger Sub I, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Parent, merging with and into Exact Sciences, with Exact Sciences surviving the Merger as a wholly owned subsidiary of Parent. Exact Sciences shareholders will receive \$105 per common share, representing a total equity value of approximately \$21 billion.

The transaction is expected to close in the second quarter of 2026, upon receipt of all required regulatory and shareholder approvals.

Statement of why transaction is necessary or desirable

Together, Abbott and Exact Sciences will reach more patients to help prevent cancer, enable earlier detection, and empower physicians and consumers with data-driven insight that support more informed personalized care. Combined with Abbott’s global scale, reputation for operational and commercial excellence and strong relationships with healthcare systems, Exact Sciences will be positioned to create a powerful, new growth platform to unlock new opportunities to build upon in the future.

A combination of Abbott and Exact Sciences will expand the availability of advanced cancer diagnostic testing to reach new patient populations, both in the US and internationally, where Exact Sciences has limited presence today. Abbott’s research and development capabilities will also accelerate innovation in early cancer screening and precision oncology testing with Exact Sciences’ products to facilitate quicker turnaround times, lower costs, and improved patient experiences.

General public impact or benefits of transaction, including quality and equity measures and impacts

With this acquisition, Abbott will enter the field of advanced cancer diagnostics, a large and rapidly growing segment. There is significant unmet clinical need in advanced cancer diagnostics as most preventable cancers go undetected and/or unscreened, and this transaction will broaden Abbott’s diagnostics capabilities across the cancer care continuum. By combining Abbott’s extensive research and development capabilities to develop instrument-based solutions for decentralized settings (e.g., physician offices, cancer centers) with Exact Sciences’ complementary suite of diagnostic products, the transaction would facilitate rapid turnaround times, lower costs, and improved patient access.

The transaction would also give Exact Sciences access to Abbott’s strong international presence, thereby fostering improved access to important cancer testing options around the world and helping more people in more places.

Description of competitive impacts of transaction and any actions or activities to mitigate any potential adverse impacts of the transaction on the public

This transaction is not a horizontal combination of competitors as Abbott and Exact Sciences do not compete today. Exact Sciences will continue to be operated as a stand-alone business and there are no current plans to integrate it with Abbott's toxicology or Acelis businesses. As a result, the parties do not anticipate adverse impacts of the transaction on the public. To the contrary, the parties expect the benefits set forth in the responses to questions above under the response to the section requesting a "statement of why the transaction is necessary or desirable" and the "general public impact or benefits of the transaction, including quality and equity measures and impacts."

Description of current services provided and expected post-transaction impacts on health care services

Counties where services are currently performed and any post-transaction changes thereto

Abbott's Redwood Toxicology Laboratory, Alere Home Monitoring, and Quality Assured Services provide services in all counties in California. These services are not impacted by the Proposed Transaction and, as a result, Abbott does not anticipate any post-transaction changes in service area coverage.

Levels and type of health care services currently offered, such as the full range of reproductive health care and sexual health care services, specialized services for LGBTQ+ populations, labor and delivery services, pediatric services, behavioral health services, cardiac services, and emergency services, and any post-transaction changes thereto

Abbott does not provide any reproductive health care or sexual health care services, specialized services for LGBTQ+ populations, labor and delivery services, pediatric services, behavioral health services, cardiac services, and emergency services. As a result, Abbott does not anticipate any post-transaction changes.

Summary that includes the number and type of patients currently served, including, but not limited to, age, gender, race, ethnicity, preferred language spoken, disability status, and payer category, and any post-transaction changes thereto

Attached as **Attachment M** is a summary that includes the number and type of patients the below-listed Abbott subsidiaries currently serve, broken down by gender, age, preferred language spoken, and payer category. Abbott does not capture patient race, ethnicity, or disability status as a part of its records. In addition, the Redwood Toxicology Laboratory does not capture patient preferred language spoken or payer category as it does not directly bill payers for services. As mentioned above, the Proposed Transaction will not affect the Existing California Service Lines and, as a result, Abbott does not anticipate any post-transaction changes to any of the health care service information included in this notice.

Current community needs assessments, charity care, and community benefit programs, and any post-transaction changes thereto

Not applicable to Abbott. As a result, Abbott does not anticipate any post-transaction changes.

Whether Medi-Cal and Medicare patients are currently accepted and any post-transaction changes thereto

Abbott provides services to Medi-Cal and Medicare beneficiaries. Because Abbott does not directly bill for Redwood Toxicology Laboratory services, Abbott does not retain records of whether donors or patients are Medi-Cal or Medicare beneficiaries and assumes such patient populations are included in the laboratory's patient demographics. Through Alere Home Monitoring, Abbott provides services to Medicare beneficiaries. However, Alere Home Monitoring does not provide services to the Medi-Cal

beneficiary population. Through Quality Assured Services, Abbott provides services to the Medi-Cal and Medicare beneficiary population. Abbott does not anticipate any post-transaction changes thereto.

Potential Post-Transaction Changes to the Following

Ownership, governance, or operational structure

Exact Sciences will continue to be operated as a stand-alone business, and there are no plans to integrate it with the entities listed in this notice that provide the Existing California Service Lines. As such, Abbott does not anticipate any structural ownership, governance, or operational changes to Abbott post-transaction.

The Submitter's employee staffing levels, job security or retraining policies, employee wages, benefits, working conditions, and employment protections

The parties do not anticipate any changes post-closing to employee staffing levels, job security or retaining policies, employee wages, benefits, working conditions, and employment protections. Exact Sciences will continue to be operated as a stand-alone business, and there are no plans to integrate it with Abbott's other businesses.

City or county contracts regarding the provision of health care services between the parties to the transaction and the cities or counties

The parties do not anticipate changes to any contracts with cities or counties regarding the provision of any laboratory services following the closing of the transaction.

If the submitter is a provider, comparable health care services currently offered by other health care entities within 20 miles of any location where the submitter offers health care services

Health care providers throughout California have a wide range of clinical laboratories from which they can order laboratory, IDTF, and DME services. Abbott is not aware of any potential post-transaction changes to comparable health services offered by other health care entities within twenty (20) miles of any location where Abbott offers services.

Provider Summary:
Provider Type, Facilities Owned/Operated, Service Lines, Number of Staff, Geographic Service Areas, and Capacity or Patients Served in California

Entity	
Abbott Toxicology Lab	<p><u>Business Address:</u> 100 Abbott Park Road, Abbott Park, IL 60064</p> <p>3650 Westwind Boulevard, Santa Rosa, CA 95403 (Redwood)</p> <p><u>Description of Business:</u> Clinical Laboratory Services</p> <p><u>Governance/Operational Structure:</u> Business Corporation</p> <p><u>California Annual Revenue (last 3 years):</u> 64,975,900 (2023); 89,091,300 (2024); 87,417.50 (Nov. 2025 YTD)</p> <p><u>Current Counties of Operation:</u> All counties in CA.</p> <p><u>Provider Type:</u> Clinical Laboratory</p> <p><u>Facilities Owned or Operated:</u> Redwood Toxicology Lab</p> <p><u>Service Lines:</u> Toxicology Clinical Lab</p> <p><u>Number of Staff:</u> 242</p> <p><u>Geographic Service Areas:</u> Provides laboratory services to all counties in CA.</p> <p><u>Capacity:</u> 2,289,955 specimens processed in the past 12 months.</p> <p><u>Patients Served in CA Last Year:</u> 639,585 (Note: this number may contain duplicates since, for example, Jennifer Doe and Jen Doe would count as separate donors)</p> <p><u>Primary and Threshold Languages:</u> English</p>
Alere Home Monitoring, Inc.	<p><u>Business Address:</u> 6465 National Drive, Livermore, CA 94550</p> <p><u>Description of Business:</u> Provides remote patient monitoring PT-INR (prothrombin time - international normalized ratio) anticoagulation services for patients on anticoagulation medicines.</p> <p><u>Governance/Operational Structure:</u> Corporation</p> <p><u>California Annual Revenue (last 3 years):</u> 4.1 million (2023); 3.5 million (2024); 3.5 million (2025).</p> <p>Current Counties of Operation: All counties in CA</p> <p><u>Provider Type:</u> IDTF</p> <p><u>Facilities Owned or Operated:</u> Livermore location</p>

Provider Summary:
Provider Type, Facilities Owned/Operated, Service Lines, Number of Staff, Geographic Service Areas, and Capacity or Patients Served in California

Entity	
	<p><u>Service Lines:</u> Remote patient monitoring</p> <p><u>Number of Staff:</u> 103</p> <p><u>Geographic Service Areas:</u> Provides services to all counties in CA.</p> <p><u>Capacity:</u> 135</p> <p><u>Patients Served in CA Last Year:</u> 4,924</p> <p><u>Primary and Threshold Languages:</u> English</p>
Quality Assured Services (d/b/a Acelis Connection Health Supplies)	<p><u>Business Address:</u> 30 South Keller Road, Suite 100, Orlando, FL 32810</p> <p><u>Description of Business:</u> Acelis provides external Ventricle assisted Device (VAD) equipment and supplies for outpatient support and remote patient monitoring where selected as a contract option</p> <p><u>Governance/Operational Structure:</u> Corporation</p> <p><u>California Annual Revenue (last 3 years):</u> 165.7 million (2023); 187.2 million (2024); 235.5 million (2025)</p> <p><u>Current Counties of Operation:</u> Currently located in Orange County (Florida) but in the process of moving to Seminole County.</p> <p><u>Provider Type:</u> Enrolled as a DME provider with CMS (Taxonomy Code 332B00000X); also enrolled as an "Other" for VAD equipment and supplies.</p> <p><u>Facilities Owned or Operated:</u> 30 S. Keller Road, Suite 100B, Orlando, FL, 32810</p> <p><u>Service Lines:</u> Durable Medical Equipment/Ventricle Assisted Devices</p> <p><u>Number of Staff:</u> 30</p> <p><u>Geographic Service Areas:</u> Contiguous US, Alaska & Hawaii</p> <p><u>Capacity:</u> Approximately 8,000 patients on DME supplies</p> <p><u>Patients Served in CA Last Year:</u> 437</p> <p><u>Primary and Threshold Languages:</u> English; Spanish: 255; Other: 262; Null: 44</p>

Patient Summary: Number and type of patients currently served, including, but not limited to, age, gender, race, ethnicity, preferred language spoken, disability status, and payer category, and any post-transaction changes thereto

Redwood Toxicology Lab	Alere Home Monitoring	Quality Assured Services
Female: 118,591 donors Male: 209,536 donors < 18: 31,983 18-30: 90,860 30-40: 106,487 40-50: 67,186 > 50: 50,667	Female: 37,995 Male: 45,718 English: 82,529 Spanish: 363 Other: 371 Null: 452 <18: 2,928 18-29: 4,110 30-39: 76,558 40-49: 229,852 50+: 5,494,569 Commercial: 45,981 Medicaid: 72 Medicare: 37,418 Self Pay: 244	Female: 2064 Male: 6,533 English: 8,036 Spanish: 255 Other: 262 Null: 44 < 18: 243 18-29: 6,332 30-39: 19,549 40-49: 46,718 50+: 447,005 Commercial: 4,402 Medicaid: 283 Medicare: 3,912

California health care-related licenses issued by regulatory agencies such as the Department of Managed Health Care, the Department of Insurance, and the Department of Public Health; state and local business licenses related to the provision of health care services; registration(s) with the Secretary of State held by the submitter.

Licensee	Agency	License Type	License #
Ascertain Forensics, Santa Rosa	ANAB	ISO 17025:2017 ABFT Forensic Toxicology Lab	FT-0409
Redwood Toxicology Laboratory, Santa Rosa	CMS	CLIA Certificate of Compliance	05D0707588
	Drug Enforcement Agency (DEA)	Controlled Substance Registration Certificate	RR0364911
	California Department of Health	Clinical Laboratory License	CLF-00003738
	City of Santa Barbara	Business License	723394
	City of San Francisco	Business Registration Certificate	0943703
	City of Oakland	Business Tax Certificate	00131613
	City of Pleasanton	Business License Certificate	1013829
	City of San Jose	Business Tax Certificate	4159622210
	Sisseton Wahpeton Oyate	Business Tax Certificate	NM-770
	City of Tracy	Business License Tax Certificate	06012166
	Mendocino County	Business License	128060
	City of Dublin	Business License	bl-112309
	El Dorado County	Business License	068322
	State of Michigan	Sales Tax License	68-0332937
	City of Redwood	Statement of Information Corporation	N/A
Alere Home Monitoring	Department of Public Health, Food and Drug Branch	Home Medical Device Retail License	54341
	City of Livermore	Business License	9907015034
	County of Alameda	Fictitious Name Filing (for Acelis Connected Health Services)	602765
Quality Assured Services	Department of Public Health, Food and Drug Branch	Home Medical Device Retail Registration	71789

Other states where health care-related licenses are held, including license type and numbers:

Licensee	State	Agency	License Type	License #
Redwood Toxicology Laboratory, Santa Rosa	Maryland	Department of Health	Medical Laboratory Permit	880
	Pennsylvania	Department of Health	Clinical Laboratory Permit	25348A
	Rhode Island	Department of Health	Out of State Clinical Laboratory License	LCO-00454
Ascertain Forensics, Santa Rosa	Texas	Texas Forensic Science Commission	Forensic Science Laboratory Accreditation	N/A
	California	Department of Health	Title 17 Forensic Alcohol Laboratory	N/A
Quality Assured Services, Inc.	Florida	Agency for Health Care Administration	Home Medical Equipment Provider	1102
	Florida	Town of Eatonville	Local Business Tax Receipt	LBT23-000046
	Florida	Orange County	Local Business Tax Receipt	3501-1068963

Row Labels	Count of County
CA	437
Alameda	20
Amador	1
Butte	10
Calaveras	2
Colusa	2
Contra Costa	11
El Dorado	2
Fresno	17
Glenn	1
Humboldt	1
Imperial	4
Kern	4
Lake	2
Los Angeles	48
Madera	4
Marin	4
Merced	6
Monterey	8
Napa	4
Nevada	1
Orange	41
Placer	6
Riverside	31
Sacramento	25
San Bernardino	18
San Diego	80
San Francisco	16
San Joaquin	8
San Mateo	4
Santa Clara	16
Shasta	2
Siskiyou	1
Solano	8
Sonoma	8
Stanislaus	3
Sutter	4
Tehama	2
Tulare	11
Ventura	1
Grand Total	437

Row Labels	Count of County
CA	4924
Alameda	233
Alpine	3
Amador	18
Butte	27
Calaveras	10
Colusa	3
Contra Costa	185
Del Norte	4
El Dorado	88
Fresno	56
Glenn	1
Humboldt	34
Imperial	12
Kern	186
Kings	5
Lake	13
Lassen	24
Los Angeles	892
Madera	15
Marin	86
Mariposa	1
Mendocino	35
Merced	17
Modoc	1
Mono	6
Monterey	48
Napa	25
Nevada	49
Orange	441
Placer	137
Plumas	7
Riverside	239
Sacramento	302
San Benito	7
San Bernardino	187
San Diego	152
San Francisco	75
San Joaquin	73
San Luis Obispo	45
San Mateo	138
Santa Barbara	104
Santa Clara	240

Alere Home Monitoring

Santa Cruz	111
Shasta	30
Sierra	3
Siskiyou	9
Solano	51
Sonoma	99
Stanislaus	73
Sutter	12
Tehama	11
Trinity	4
Tulare	33
Tuolumne	12
Ventura	180
Yolo	57
Yuba	15
Grand Total	4924